Google’s Verily snapped up Raleigh, N.C.-based SignalPath and the company’s clinical trial management system that is expected to support its own clinical trial and evidence-based platform known as Baseline.
Bayer AG is buying Vividion Therapeutics, a San Diego-based company that focuses on drug development using protein surface screening, in a $2 billion deal.
Amgen is snapping up privately held Teneobio and the company’s class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.
In PerkinElmer’s largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy the biomedical research tool company BioLegend.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced the acquisition of Accelera Canada and its partner companies Patient Access Solutions, Podium Strategic Partners Inc. and Advocacy Solutions.
Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.
Indianapolis-based Eli Lilly and Company is acquiring Pasadena, Calif.-based Protomer Technologies in a deal that may exceed $1 billion.
Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp.’s experimental heart therapy PRX004 in a deal that could be worth up to $1.23 billion, the companies said on July 12.
Shares of U.K.-based Vectura Group were up more than 13% in trading after Philip Morris International announced the tobacco giant’s plans to acquire the company for $1.44 billion in cash.
St. Jude Medical, which was acquired by Abbott Laboratories in 2017, agreed to pay $27 million to settle allegations the company knowingly sold defective heart devices, the U.S. Justice Department said on July 8.